IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10415-10431

  Liu, Yi Nan ^a   Chang, Tzu Hua ^a   Tsai, Meng Feng ^b   Wu, Shang Gin ^a   Tsai, Tzu Hsiu ^a   Chen, Hsuan Yu ^c   Yu, Sung Liang ^d   Yang, James Chih Hsin ^a,d   Shih, Jin Yuan ^a,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b DA YEH UNIVERSITY   (Taiwan)

^c INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

EGFR; Gefitinib; IL 8; Resistance; Stemness

Indexed keywords

ALDEHYDE DEHYDROGENASE; BMI1 PROTEIN; ERLOTINIB; GEFITINIB; INTERLEUKIN 8; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; RECOMBINANT INTERLEUKIN 8; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; IL8 PROTEIN, HUMAN; MESSENGER RNA; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ALDH1A1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BMI1 GENE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL DEATH; CELL LOSS; CELL POPULATION; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IL 8 GENE; IN VIVO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NANOG GENE; NESTIN GENE; NON SMALL CELL LUNG CANCER; NONHUMAN; OCT4 GENE; PC9 CELL LINE; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SOX 2 GENE; UPREGULATION; VERY ELDERLY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; STEM CELL; TUMOR CELL LINE; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; HETEROGRAFTS; HUMANS; INTERLEUKIN-8; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84929591022     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3389     Document Type: Article

References (48)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139.
3. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013; 31:1070-1080.
4. Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, Wu CP, Shih JY, Yang PC. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011; 183:1071-1079.
5. Li X, Ma Q, Xu Q, Liu H, Lei J, Duan W, Bhat K, Wang F, Wu E, Wang Z. Sdf-1/cxcr4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of hedgehog pathway. Cancer Lett. 2012; 322:169-176.
6. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. Il-8 signaling plays a critical role in the epithelialmesenchymal transition of human carcinoma cells. Cancer Res. 2011; 71:5296-5306.
7. Ploenes T, Scholtes B, Krohn A, Burger M, Passlick B, Muller-Quernheim J, Zissel G. Cc-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer a549 cells and elevates the invasive potential. PLoS One. 2013; 8:e53068.
8. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massague J. A cxcl1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012; 150:165-178.
9. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, Chung S, Luther T, Paholak HJ, et al. Activation of an il6 inflammatory loop mediates trastuzumab resistance in her2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012; 47:570-584.
10. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG, Lee JS, Lee SJ, Lee JC, Park MJ. Upregulation of cxcr4 is functionally crucial for maintenance of stemness in drugresistant non-small cell lung cancer cells. Oncogene. 2013; 32:209-221.
11. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS. Cxcr1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010; 120:485-497.
12. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5:275-284.
13. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009; 8:806-823.
14. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, philadelphia- positive stem cells from patients with chronic myeloid leukemia are insensitive to sti571 in vitro. Blood. 2002; 99:319-325.
15. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther. 2008; 3:237-246.
16. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact. 2009; 178:48-55.
17. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007; 67:4827-4833.
18. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih JY, Lin SB. Aldh-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013; 328:144-151.
19. Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, Tsukuda K, Takigawa N, Kiura K, et al. Acquired resistance to egfr inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013; 73:3051-3061.
20. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM, Yang JC. Mek inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013; 7:112-120.
21. Sun X, Mao Y, Wang J, Zu L, Hao M, Cheng G, Qu Q, Cui D, Keller ET, Chen X, Shen K, Wang J. Il-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene 2014.
22. Singh RK, Varney ML. Il-8 expression in malignant melanoma: Implications in growth and metastasis. Histol Histopathol. 2000; 15:843-849.
23. Singh RK, Lokeshwar BL. Depletion of intrinsic expression of interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer. 2009; 8:57.
24. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005; 7:122-133.
25. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14:6735-6741.
26. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. Egfr mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352:786-792.
27. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011; 128:2038-2049.
28. Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor cxcr4 in lung cancer. Cancer Biol Ther. 2010; 9:409-416.
29. Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine. 2011; 56:365-375.
30. Ahmed OI, Adel AM, Diab DR, Gobran NS. Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol. 2006; 13:61-68.
31. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004; 10:7157-7162.
32. Orditura M, De Vita F, Catalano G, Infusino S, Lieto E, Martinelli E, Morgillo F, Castellano P, Pignatelli C, Galizia G. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis. J Interferon Cytokine Res. 2002; 22:1129-1135.
33. Sanmamed MF, Carranza-Rua O, Alfaro C, Onate C, Martin-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, Munoz-Calleja C, Rodriguez-Ruiz M, Sangro B, et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res. 2014; 20:5697-5707.
34. Song XY, Zhou SJ, Xiao N, Li YS, Zhen DZ, Su CY, Liu ZD. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer. Asian Pac J Cancer Prev. 2013; 14:4765-4768.
35. Ryan BM, Pine SR, Chaturvedi AK, Caporaso N, Harris CC. A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Thorac Oncol. 2014; 9:1494-1503.
36. Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/ cxcl8 is a growth factor for human lung cancer cells. Br J Cancer. 2004; 91:1970-1976.
37. Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W, Yuan Z, Wang LH, Cheng JQ. Advances of akt pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets. 2008; 8:2-6.
38. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. Nf-kappab functions as a tumour promoter in inflammation-associated cancer. Nature. 2004; 431:461-466.
39. Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q, Zhu J, Chen JJ, Huang RC, Chen ZS, Huang RP. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of il-6 and il-8 production. Breast Cancer Res Treat. 2012; 135:737-747.
40. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer. 2007; 56:25-33.
41. Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: Evidence and controversies. Respirology. 2013; 18:757-764.
42. Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, Iwakami S, Moriyama M, Moriyama H, et al. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One. 2014; 9:e86459.
43. Infanger DW, Cho Y, Lopez BS, Mohanan S, Liu SC, Gursel D, Boockvar JA, Fischbach C. Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res. 2013; 73:7079-7089.
44. Park SY, Han J, Kim JB, Yang MG, Kim YJ, Lim HJ, An SY, Kim JH. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. Eur J Cancer. 2014; 50:341-350.
45. Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, Teng HW, Yang SH, Lan YT, Chiou SH, Wang HW. Snail regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology. 2011; 141:279-291, 291 e271-275.
46. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS One. 2008; 3:e3077.
47. Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, et al. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012; 132:2440-2450.
48. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The abc transporter bcrp1/ abcg2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001; 7:1028-1034.